Bayer’s Rally Has Roots Beyond the Courtroom: Pipeline Acquisitions and AI Deals Fuel the Momentum
26.06.2026 - 15:57:12 | boerse-global.de
Bayer has stormed to the top of the DAX momentum leaderboard with a 30-day gain of 23.75%, leaving the second-best performer Merck trailing by more than 13 percentage points. But this surge is not solely a story of legal relief — the Leverkusen-based group has been quietly assembling a multibillion-dollar pipeline that is starting to capture investor attention.
The stock now trades at €46.54, roughly 7% below its 52-week high of €49.93 set in February. While the Supreme Court’s recent Roundup decision has dominated headlines, the rally’s durability rests on a series of concrete strategic moves that have reshaped the group’s growth narrative.
Eye-Care Bet Worth Up to $2.45 Billion
Bayer completed the acquisition of Perfuse Therapeutics in June 2026, securing full rights to PER-001, a phase-II intravitreal implant targeting glaucoma and diabetic retinopathy — conditions affecting up to 80 million and 146 million people globally, respectively. The upfront payment was $300 million, with the total deal value potentially reaching $2.45 billion depending on development and regulatory milestones. PER-001 is positioned as a potential first-in-class small-molecule endothelin receptor antagonist implant, with no comparable therapy currently on the market.
Should investors sell immediately? Or is it worth buying Bayer?
AI Collaboration and FDA Nod
In the same month, Bayer announced a research partnership with Iambic Therapeutics, a company that uses an AI-driven platform to identify novel drug targets. The collaboration leverages Iambic’s Enchant and NeuralPLexer technologies to tackle hard-to-drug targets. Bayer did not disclose specific financial terms.
Regulatory progress also contributed to the positive sentiment. The FDA approved Bayer’s contrast agent AMBELVIST in June, while established products Nubeqa and Kerendia continue to post significant sales gains. Positive phase-III data for Asundexian in stroke prevention had already emerged in February.
Debt Lightens, but Cash Flow Remains Under Pressure
The operational momentum should not obscure the financial realities. Bayer reduced net debt from €32.6 billion to €29.8 billion in 2025, with free cash flow of €2.1 billion. However, the company expects cash outflows of around €5 billion in 2026 alone for litigation costs, likely pushing free cash flow into negative territory. The Supreme Court ruling could eventually ease that burden — legal battles over glyphosate have already cost Bayer more than $10 billion. A final hearing on the Missouri settlement is scheduled for July 9, 2026, and a positive outcome would further solidify the legal resolution.
Technical Signals Flash Overheating
The speed of the rally has pushed the relative strength index to 80.5, firmly in overbought territory. The annualized volatility stands at nearly 58%, underscoring how skittish the stock remains. Unlike peers such as Merck or Henkel, where momentum has been steadier and technical indicators more moderate, Bayer’s move looks like a bet on a fundamental re-rating that is still a work in progress. Investors are buying a turnaround story, not a finished product — and the coming weeks will test whether the capital flows into pharma and consumer staples persist or rotate into other corners of the DAX.
Ad
Bayer Stock: New Analysis - 26 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
